» Articles » PMID: 32601341

Rescue of Mutant Gonadotropin-releasing Hormone Receptor Function Independent of Cognate Receptor Activity

Overview
Journal Sci Rep
Specialty Science
Date 2020 Jul 1
PMID 32601341
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Molecules that correct the folding of protein mutants, restoring their functional trafficking, are called pharmacoperones. Most are clinically irrelevant and possess intrinsic antagonist or agonist activity. Here, we identify compounds capable of rescuing the activity of mutant gonadotropin-releasing hormone receptor or GnRHR which, is sequestered within the cell and if dysfunctional leads to Hypogonadotropic Hypogonadism. To do this we screened the E90K GnRHR mutant vs. a library of 645,000 compounds using a cell-based calcium detection system. Ultimately, we identified 399 compounds with EC ≤ 5 µM with no effect in counterscreen assays. Medicinal chemistry efforts confirmed activity of 70 pure samples and mode of action studies, including radioligand binding, inositol phosphate, and toxicity assays, proved that we have a series of tractable compounds that can be categorized into structural clusters. These early lead molecules rescue mutant GnRHR function and are neither agonist nor antagonists of the GnRHR cognate receptor, a feature required for potential clinical utility.

Citing Articles

Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism.

Fanis P, Neocleous V, Papapetrou I, Phylactou L, Skordis N Int J Mol Sci. 2023; 24(21).

PMID: 37958948 PMC: 10650312. DOI: 10.3390/ijms242115965.


Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.

Ulloa-Aguirre A, Zarinan T, Gutierrez-Sagal R, Tao Y Front Endocrinol (Lausanne). 2022; 13:934685.

PMID: 36093106 PMC: 9452723. DOI: 10.3389/fendo.2022.934685.


Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel.

Chulkov E, Smith E, Rohr C, Yahya N, Park S, Scampavia L PLoS Negl Trop Dis. 2021; 15(11):e0009898.

PMID: 34731172 PMC: 8565742. DOI: 10.1371/journal.pntd.0009898.

References
1.
Conn P, Janovick J . Drug development and the cellular quality control system. Trends Pharmacol Sci. 2009; 30(5):228-33. DOI: 10.1016/j.tips.2009.02.002. View

2.
Janovick J, Maya-Nunez G, Conn P . Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 2002; 87(7):3255-62. DOI: 10.1210/jcem.87.7.8582. View

3.
Conn P, Ulloa-Aguirre A . Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab. 2009; 21(3):190-7. PMC: 2831145. DOI: 10.1016/j.tem.2009.11.003. View

4.
Janovick J, Goulet M, Bush E, Greer J, Wettlaufer D, Conn P . Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther. 2003; 305(2):608-14. DOI: 10.1124/jpet.102.048454. View

5.
Ulloa-Aguirre A, Zarinan T, Dias J, Conn P . Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. Mol Cell Endocrinol. 2013; 382(1):411-423. PMC: 3844050. DOI: 10.1016/j.mce.2013.06.024. View